Fifth Third Wealth Advisors LLC Purchases 278 Shares of Edwards Lifesciences Co. (NYSE:EW)

Fifth Third Wealth Advisors LLC increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,584 shares of the medical research company’s stock after acquiring an additional 278 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $413,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. J.W. Cole Advisors Inc. boosted its position in shares of Edwards Lifesciences by 7.4% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 2,956 shares of the medical research company’s stock valued at $273,000 after acquiring an additional 204 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Edwards Lifesciences by 18.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock valued at $129,271,000 after purchasing an additional 219,486 shares during the last quarter. Edgestream Partners L.P. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $438,000. Bradley Foster & Sargent Inc. CT increased its holdings in shares of Edwards Lifesciences by 17.9% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 16,842 shares of the medical research company’s stock worth $1,556,000 after buying an additional 2,563 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. raised its position in shares of Edwards Lifesciences by 1.2% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after buying an additional 184 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on EW. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Royal Bank of Canada increased their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Robert W. Baird decreased their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Stock Performance

Shares of EW opened at $69.87 on Friday. The company has a 50-day simple moving average of $71.91 and a two-hundred day simple moving average of $71.61. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $41.21 billion, a PE ratio of 10.08, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock worth $2,195,180 in the last three months. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.